TrialSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.

John Glaspy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.